Innoviva Inc. Stock
Price
Target price
?
?
0.000%
-
0.000%
€35.73
09:31 / Stuttgart Stock Exchange
WKN: A2AC9U / Symbol: INVA / Name: Innoviva / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Innoviva Inc. Stock
The Innoviva Inc. price is unchanged compared to yesterday.
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Innoviva Inc..
With a target price of 35 € there is a hugely positive potential of 76.77% for Innoviva Inc. compared to the current price of 19.8 €.
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | 0.000% | 3.763% | -0.515% | 3.763% | 17.683% | 59.504% | 93.970% |
| Rockwell Medical Inc. | 0.000% | 2.586% | -13.768% | -33.631% | -12.047% | -85.766% | -92.952% |
| Pacira Pharmaceuticals | 0.990% | 4.737% | 1.015% | -7.870% | -7.870% | -40.060% | -58.714% |
| Twist Bioscience Corp | -2.610% | -5.871% | 21.617% | 94.433% | 110.700% | 263.344% | -36.078% |
Comments
Innoviva (INVA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its price target raised by BTIG Research from $35.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INVA provided by MarketBeat
News
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Dauntless Investment Group disclosed in a May 14, 2026, SEC filing that it bought 116,863 shares of Innoviva (NASDAQ:INVA), an estimated $2.52 million trade based on quarterly average pricing.
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also
